The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
AASLD guidelines for the treatment of hepatocellular carcinoma
Open accessAbstract
Potential conflict of interest: Laura M. Kulik is on the advisory board for Gilead, Bayer, Eisai, Salix, and Bristol‐Myers Squibb. Richard Finn consults for Pfizer, Bayer, Novartis, Merck, and Bristol‐Myers Squibb. Claude B. Sirlin consults for and has received grants from Virtualscopics. Lewis R. Roberts consults for Wako, Medscape, and Axis; advises Tavec and Bayer; is on the speakers' bureau for Onlive; and has received grants from Ariad, BTG, and Gilead. Andrew Zhu consults for Bristol‐Myers Squibb, Eisai, Merck, Novartis, Sanofi, and Bayer. The funding for the development of this Practice Guideline was provided by the American Association for the Study of Liver Diseases. Guiding Principles and Objectives GUIDING PRINCIPLES This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the surveillance, diagnosis, and treatment of hepatocellular carcinoma (HCC) occurring in the setting of adults with cirrhosis. Unlike previous AASLD practice guidelines, the current guideline was developed in compliance with the Institute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.1 Multiple systematic reviews of the literature were conducted to support the recommendations in this practice guideline. An enhanced understanding of the guideline can be obtained by reading the applicable portions of the systematic reviews. In addition, more detailed information may be found in the associated guidance document related to clinically important aspects of HCC that lacked sufficient evidence to warrant a systematic review. The guideline focuses on a broad spectrum of clinical practice, including surveillance of patients with cirrhosis for HCC, establishing the diagnosis of HCC, and various therapeutic options for the treatment of HCC. To address other issues on HCC such as epidemiology, staging, and additional aspects of diagnosis and treatment, the authors have created a new guidance document that will be published soon and is based upon the previous HCC AASLD guidelines by Bruix and Sherman.2 KEY QUESTIONS The guideline developers from the AASLD identified key questions that health care providers are faced with frequently in the evaluation and management of patients with HCC. These questions were: Should adults with cirrhosis undergo surveillance for HCC? If so, which surveillance test is best? Should adults with cirrhosis and suspected HCC undergo diagnostic evaluation with multiphasic computed tomography (CT) or multiphasic magnetic resonance imaging (MRI)? Should adults with cirrhosis and an indeterminate hepatic nodule undergo a biopsy, repeated imaging, or alternative imaging for the diagnostic evaluation? Should adults with Child‐Pugh class A cirrhosis and early‐stage HCC (T1 or T2) be treated with resection or local‐regional (LRT) therapy? Should adults with cirrhosis and HCC that has been resected or ablated successfully undergo adjuvant therapy? Should adults with cirrhosis awaiting liver transplantation and HCC (T1) be treated or undergo observation? Should adults with cirrhosis and HCC (Organ Procurement and Transplantation Network [OPTN] T2) awaiting liver transplantation undergo transplantation alone or transplantation with bridging therapy while waiting? Should adults with cirrhosis awaiting liver transplantation and HCC beyond Milan criteria (T3) undergo transplantation after being down‐staged to within Milan criteria? Should adults with cirrhosis and HCC (T2 or T3, no vascular involvement) who are not candidates for resection or transplantation be treated with transarterial chemoembolization, transarterial radioembolization, or external radiation? Should adults with Child‐Pugh class A/B cirrhosis and advanced HCC with macrovascular invasion and/or metastatic disease be treated with systemic or locoregional therapies or no therapy? TARGET AUDIENCE This guideline is intended primarily for health care providers who care for patients with cirrhosis. Additionally, the guideline may inform policy decisions regarding patients with HCC. Background BURDEN OF DISEASE According to the World Health Organization, HCC is the fifth most common tumor worldwide and the second most common cause of cancer‐related death (http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp). Male‐to‐female predominance is greater than 2:1 with liver cancer, and approximately 83% of the estimated 782,000 new HCC cases in 2012 occurred in less developed regions of the world, with East and South Asia plus sub‐Saharan Africa being the regions of highest incidence, Southern Europe and North America being the regions of intermediate incidence, and Northern Europe and South Central Asia being the regions of lowest incidence.3 The incidence of HCC has been rising rapidly in the United States over the last 20 years.4 According to estimates from the Surveillance Epidemiology End Results
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Lo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Randomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496
Chen, M.-S., Li, J.-Q., Zheng, Y., Guo, R.-P., Liang, H.-H., Zhang, Y.-Q., Lin, X.-J., & Lau, W. Y. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000201480.65519.b8 · Cited by 1,432
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120
Forner, A., Vilana, R., Ayuso, C., Bianchi, L., Solé, M., Ayuso, J. R., Boix, L., Sala, M., Varela, M., Llovet, J. M., et al. (2008) · Hepatology · doi:10.1002/hep.21966 · Cited by 1,032
Clavien, P.-A., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70175-9 · Cited by 1,026
Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., Foschi, F. G., Lenzi, M., Mazzella, G., Verucchi, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.015 · Cited by 897
Huang, J., Yan, L., Cheng, Z., Wu, H., Du, L., Wang, J., Xu, Y., & Zeng, Y. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181efc656 · Cited by 844
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Self-citationSingal, A. G., Pillai, A., & Tiro, J. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001624 · Cited by 817
Feng, K., Yan, J., Li, X., Xia, F., Ma, K., Wang, S., Bie, P., & Dong, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.05.007 · Cited by 767
Poon, R. T.-P., Fan, S.-T., Ng, I. O.-L., Lo, C.-M., Liu, C.-L., & Wong, J. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<500::aid-cncr4>3.0.co;2-o · Cited by 729
Salem, R., Gordon, A. C., Mouli, S., Hickey, R., Kallini, J., Gabr, A., Mulcahy, M. F., Baker, T., Abecassis, M., Miller, F. H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.029 · Cited by 691
Self-citationMuto, Y., Moriwaki, H., Ninomiya, M., Adachi, S., Saito, A., Takasaki, K. T., Tanaka, T., Tsurumi, K., Okuno, M., Tomita, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342402 · Cited by 668
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Self-citationLiver Transplantation for Hepatocellular Carcinoma
Bismuth, H., Majno, P., & Adam, R. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007120 · Cited by 561
Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. D. C., Vilana, R., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270617 · Cited by 533
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
Petrick, J. L., Kelly, S. P., Altekruse, S. F., McGlynn, K. A., & Rosenberg, P. S. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7412 · Cited by 442
Pelletier, G., Roche, A., Ink, O., Anciaux, M. L., Derhy, S., Rougier, P., Lenoir, C., Attali, P., & Etienne, J.-P. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90110-d · Cited by 417
Sangiovanni, A., Manini, M. A., Iavarone, M., Romeo, R., Forzenigo, L. V., Fraquelli, M., Massironi, S., Della Corte, C., Ronchi, G., Rumi, M. G., et al. (2010) · Gut · doi:10.1136/gut.2009.187286 · Cited by 408
Pelletier, G., Ducreux, M., Gay, F., Luboinski, M., Hagège, H., Thong, D., Van Steenbergen, W., Buffet, C., Rougier, P., Adler, M., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80187-6 · Cited by 396
Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus Infection
Kanwal, F., Hoang, T., Kramer, J. R., Asch, S. M., Goetz, M. B., Zeringue, A., Richardson, P., & El–Serag, H. B. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.12.032 · Cited by 395
Llovet, J. M., Bruix, J., Fuster, J., Castells, A., Garcia-Valdecasas, J. C., Grande, L., França, A., Brú, C., Navasa, M., Ayuso, M. D., et al. (1998) · Hepatology · doi:10.1002/hep.510270616 · Cited by 382
International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007
Petrick, J. L., Braunlin, M., Laversanne, M., Valery, P. C., Bray, F., & McGlynn, K. A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30211 · Cited by 342
Yin, L., Li, H., Li, A.-J., Lau, W. Y., Pan, Z.-Y., Lai, E. C. H., Wu, M.-C., & Zhou, W.-P. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.012 · Cited by 334
Liver and Intestine Transplantation in the United States, 1997–2006
Freeman, R. B., Steffick, D. E., Guidinger, M. K., Farmer, D. G., Berg, C. L., & Merion, R. M. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02174.x · Cited by 333
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States
Makarova‐Rusher, O. V., Altekruse, S. F., McNeel, T. S., Ulahannan, S., Duffy, A. G., Graubard, B. I., Greten, T. F., & McGlynn, K. A. (2016) · Cancer · doi:10.1002/cncr.29971 · Cited by 332
Basic Issues in Population Screening for Cancer 23
(1980) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/64.5.1263 · Cited by 321
Stigliano, R., Marelli, L., Yu, D., Davies, N., Patch, D., & Burroughs, A. K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.04.001 · Cited by 311
Pompili, M., Saviano, A., de Matthaeis, N., Cucchetti, A., Ardito, F., Federico, B., Brunello, F., Pinna, A. D., Giorgio, A., Giulini, S. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.009 · Cited by 285
Downstaging hepatocellular carcinoma: A systematic review and pooled analysis
Parikh, N. D., Waljee, A. K., & Singal, A. G. (2015) · Liver Transplantation · doi:10.1002/lt.24169 · Cited by 273
Yao, F. Y., Bass, N. M., Nikolai, B., Merriman, R., Davern, T. J., Kerlan, R., Ascher, N. L., & Roberts, J. P. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50147 · Cited by 271
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Oliveri, R. S., Wetterslev, J., & Gluud, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004787.pub2 · Cited by 268
Comparison of hepatocellular carcinoma in Eastern versus Western populations
Choo, S. P., Tan, W. L., Goh, B. K. P., Tai, W. M., & Zhu, A. X. (2016) · Cancer · doi:10.1002/cncr.30237 · Cited by 264
Self-citationCheng, A.-L., Guan, Z., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Yang, T.-S., Tak, W. Y., Pan, H., Yu, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.006 · Cited by 259
Huo, Y. R., & Eslick, G. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2189 · Cited by 238
Rimola, J., Forner, A., Tremosini, S., Reig, M., Vilana, R., Bianchi, L., Rodríguez-Lope, C., Solé, M., Ayuso, C., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.004 · Cited by 182
Kolligs, F. T., Bilbao, J. I., Jakobs, T., Iñarrairaegui, M., Nagel, J. M., Rodriguez, M., Haug, A., D'Avola, D., op den Winkel, M., Martinez‐Cuesta, A., et al. (2015) · Liver International · doi:10.1111/liv.12750 · Cited by 171
Sersté, T., Barrau, V., Ozenne, V., Vullierme, M., Bédossa, P., Farges, O., Valla, D. C., Vilgrain, V., Paradis, V., & Degos, F. (2011) · Hepatology · doi:10.1002/hep.24746 · Cited by 151
Vincenzi, B., Maïo, M. D., Silletta, M., D’Onofrio, L., Spoto, C., Piccirillo, M. C., Daniele, G., Comito, F., Maci, E., Bronte, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133488 · Cited by 150
Song, D. S., Song, M. J., Bae, S. H., Chung, W. J., Jang, J. Y., Kim, Y. S., Lee, S. H., Park, J. Y., Yim, H. J., Cho, S. B., et al. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0978-3 · Cited by 149
The place of downstaging for hepatocellular carcinoma
Toso, C., Mentha, G., Kneteman, N. M., & Majno, P. E. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.032 · Cited by 141
Update on Biomarkers of Hepatocellular Carcinoma
Chaiteerakij, R., Addissie, B. D., & Roberts, L. R. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.10.038 · Cited by 137
Self-citationBridging Locoregional Therapy for Hepatocellular Carcinoma Prior to Liver Transplantation
Heckman, J. T., DeVera, M., Marsh, J. W., Fontes, P., Amesur, N. B., Holloway, S. E., Nalesnik, M. A., Geller, D. A., Steel, J. L., & Gamblin, T. C. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0071-3 · Cited by 136
Nakazawa, T., Hidaka, H., Shibuya, A., Okuwaki, Y., Tanaka, Y., Takada, J., Minamino, T., Watanabe, M., Kokubu, S., & Koizumi, W. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-84 · Cited by 130
Darnell, A., Forner, A., Rimola, J., Reig, M., García‐Criado, Á., Ayuso, C., & Bruix, J. (2015) · Radiology · doi:10.1148/radiol.15141132 · Cited by 129
Liu, H., Wang, Z.-G., Fu, S.-Y., Li, A.-J., Pan, Z.-Y., Zhou, W.-P., Wy, L., & Wu, M.-C. (2016) · British journal of surgery · doi:10.1002/bjs.10061 · Cited by 124
Weis, S., Franke, A., Mössner, J., Jakobsen, J. C., & Schoppmeyer, K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003046.pub3 · Cited by 120
Nephrogenic Systemic Fibrosis: History and Epidemiology
Thomsen, H. S. (2009) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2009.05.003 · Cited by 107
Facciorusso, A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i16.2009 · Cited by 103
Hsiang, J. C., Wong, G. L., Tse, Y., Wong, V. W., Yip, T. C., & Chan, H. L. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.009 · Cited by 102
Tanabe, M., Kanki, A., Wolfson, T. J., Costa, E. A. C., Mamidipalli, A., Ferreira, M. P. F. D., Santillan, C., Middleton, M. S., Gamst, A. C., Kono, Y., et al. (2016) · Radiology · doi:10.1148/radiol.2016152173 · Cited by 98
Self-citationPeretinoin Study Group, Okita, K., Izumi, N., Matsui, O., Tanaka, K., Kaneko, S., Moriwaki, H., Ikeda, K., Osaki, Y., Numata, K., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-0956-9 · Cited by 90
Doffoël, M., Bonnetain, F., Bouché, O., Vetter, D., Abergel, A., Fratté, S., Grangé, J., Stremsdoerfer, N., Blanchi, A., Bronowicki, J., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.004 · Cited by 88
Kim, G., Shim, J. H., Yoon, S. M., Jung, J., Kim, J. H., Ryu, M., Ryoo, B., Kang, Y., Lee, D., Kim, K. M., et al. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2014.10.019 · Cited by 83
Contrast-induced nephropathy in CT: incidence, risk factors and strategies for prevention
Tao, S. M., Wichmann, J. L., Schoepf, U. J., Fuller, S. R., Lu, G., & Zhang, L. J. (2015) · European Radiology · doi:10.1007/s00330-015-4155-8 · Cited by 75
Leoni, S., Piscaglia, F., Granito, A., et al. (2013) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0033-1335024 · Cited by 73
Manini, M. A., Sangiovanni, A., Fornari, F., Piscaglia, F., Biolato, M., Fanigliulo, L., Ravaldi, E., Grieco, A., & Colombo, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.006 · Cited by 67
Mehta, N. J., Sarkar, M., Dodge, J. L., Fidelman, N. A., Roberts, J. P., & Yao, F. Y. (2015) · Liver Transplantation · doi:10.1002/lt.24360 · Cited by 66
Khalili, K., Kim, T. K., Jang, H., Yazdi, L. K., Guindi, M. M., & Sherman, M. (2010) · Hepatology · doi:10.1002/hep.24638 · Cited by 66
Wang, J., He, X., Yao, N., Liang, W. J., & Zhang, Y. C. (2013) · Canadian Journal of Gastroenterology · doi:10.1155/2013/417894 · Cited by 63
Current systemic treatment of hepatocellular carcinoma: A review of the literature
Chen, K.-W. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i10.1412 · Cited by 63
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma
Abdel-Rahman, O. M., & Elsayed, Z. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011313.pub2 · Cited by 59
Effect and Safety of Interferon for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Zhuang, L., Zeng, X., Yang, Z., & Meng, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061361 · Cited by 52
Hwang, S. H., Yu, J., Kim, K. W., Kim, J. H., & Chung, J. B. (2008) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e318064c76b · Cited by 41
Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma
Park, S., Freise, C. E., Hirose, R., Kerlan, R. K., Yao, F. Y., Roberts, J. P., & Vagefi, P. A. (2012) · Clinical Transplantation · doi:10.1111/j.1399-0012.2012.01668.x · Cited by 38
Li, Q., Wang, J., Sun, Y. K., Cui, Y., Juzi, J. T., Qian, B., & Hao, X. (2006) · Digestive Surgery · doi:10.1159/000095396 · Cited by 35
Research works printed but not linked: 20
- 2015, Screening fundamentals, J Natl Cancer Inst Monogr, 1997, 15
- 1980, Basic issues in population screening for cancer, J Natl Cancer Inst, 64, 1263
- 2009, Small nodules (1–2ccm) in liver cirrhosis: characterization with contrast‐enhanced ultrasound, Eur J Radiol, 72, 418, 10.1016/j.ejrad.2008.08.011 · doi:10.1016/j.ejrad.2008.08.011
- 2010, The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria, Am J Gastroenterol, 105, 599, 10.1038/ajg.2009.654 · doi:10.1038/ajg.2009.654
- 2008, Contrast‐enhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver, Dig Liver Dis, 40, 206, 10.1016/j.dld.2007.10.006 · doi:10.1016/j.dld.2007.10.006
- 2015, Contrast‐enhanced ultrasound for the differentiation of small atypical hepatocellular carcinomas from dysplastic nodules in cirrhosis, Dig Liver Dis, 47, 775, 10.1016/j.dld.2015.05.001 · doi:10.1016/j.dld.2015.05.001
- 2005, Importance of small (≤20‐mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver, Radiology, 237, 938, 10.1148/radiol.2373041364 · doi:10.1148/radiol.2373041364
- 2005, Outcome of small (10‐20 mm) arterial phase‐enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease, Am J Gastroenterol, 100, 1523, 10.1111/j.1572-0241.2005.41814.x · doi:10.1111/j.1572-0241.2005.41814.x
- 2007, The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver, Am J Gastroenterol, 102, 1654, 10.1111/j.1572-0241.2007.01338.x · doi:10.1111/j.1572-0241.2007.01338.x
- 2008, Small hypervascular hepatocellular carcinoma: limited value of portal and delayed phases on dynamic magnetic resonance imaging, Acta Radiologica, 49, 735, 10.1080/02841850802120045 · doi:10.1080/02841850802120045
- 2008, Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three‐dimensional gadobenate dimeglumine‐enhanced hepatic arterial‐phase MRI of the hepatitis B virus‐induced mild cirrhosis, Clin Imaging, 32, 453, 10.1016/j.clinimag.2008.05.002 · doi:10.1016/j.clinimag.2008.05.002
- 2010, Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver, J Magn Reson Imaging, 32, 360, 10.1002/jmri.22271 · doi:10.1002/jmri.22271
- 2011, Analysis of gadobenate dimeglumine–enhanced MR findings for characterizing small (1–2‐cm) hepatic nodules in patients at high risk for hepatocellular carcinoma, Radiology, 259, 730, 10.1148/radiol.11101549 · doi:10.1148/radiol.11101549
- 2008, Validation of the HCC‐MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy, Clin Transplant, 22, 469, 10.1111/j.1399-0012.2008.00811.x · doi:10.1111/j.1399-0012.2008.00811.x
- 2015, Transarterial chemoembolization prior to liver transplantation in patients with hepatocellular carcinoma, Ann Transplant, 20, 764, 10.12659/AOT.896778 · doi:10.12659/aot.896778
- 2013, Tumor biology and pre‐transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation, Clin Transplant, 27, 311, 10.1111/ctr.12089 · doi:10.1111/ctr.12089
- 2004, Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial, Liver Int, 24, 625, 10.1111/j.1478-3231.2004.0963.x · doi:10.1111/j.1478-3231.2004.0963.x
- 1993, Treatment of unresectable hepatocellular carcinoma (HCC) by lipiodol‐targeted transcatheter arterial chemoembolization (TACE). A multicenter randomized trial, Hepatology, 18, A58, 10.1016/0270-9139(93)91759-L · doi:10.1016/0270-9139(93)91759-l
- 2001, Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC), J Hepatol, 34, 11, 10.1016/S0168-8278(01)80036-2 · doi:10.1016/s0168-8278(01)80036-2
- 2015, Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta‐analysis of randomized controlled trials, Int J Clin Exp Med, 8, 10388
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationMarrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Self-citationBCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Metadata
- Authors
- Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A.
- Venue
- Hepatology
- Published
- 2017-12-19
- Volume
- 67
- Issue
- 1
- Pages
- 358-380
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2582878252
- Cited by
- 4,070
- References
- 78
- FWCI
- 191.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.